GleamWall
中文EN

TRVI Trevi Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1563880 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY-8.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-24.7%
ROA-23.8%
ROIC (approx.)-27.2%
Asset turnover—

Leverage & solvency

Liabilities / assets2.6%
Debt / equity0.00x
Current ratio38.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$33.48M$39.38M
SG&A expense$15.85M$12.15M
Operating income-$49.33M-$51.52M
Interest expense$0$4,000
Pretax income-$42.82M-$47.94M
Income tax-$64,000-$30,000
Net income-$42.76M-$47.91M
EBITDA-$49.18M-$51.38M
EPS (basic)-0.32-0.47
EPS (diluted)-0.32-0.47
Weighted avg. shares (diluted)134.75M101.97M
Balance sheet
Cash & equivalents$18.91M$34.10M
Short-term investments$169.35M$73.53M
Current assets$191.66M$109.43M
PP&E, net$178,000$157,000
Total assets$193.44M$110.90M
Current liabilities$9.75M$10.51M
Total liabilities$10.20M$11.26M
Shareholders' equity$183.24M$99.64M
Shares outstanding128.31M93.60M
Cash flow statement
Operating cash flow-$42.09M-$38.26M
Capital expenditure$12,000$35,000
Free cash flow-$42.10M-$38.29M
Investing cash flow-$94.11M-$21.53M
Financing cash flow$121.01M$61.48M
Depreciation & amortization$144,000$147,000
Stock-based compensation$5.18M$3.59M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.